STOCK TITAN

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

ADC Therapeutics (NYSE: ADCT) has granted stock options to two new employees to purchase a total of 128,600 common shares, effective April 1, 2025. The grants, approved by the Company's Compensation Committee under the Inducement Plan, serve as material employment incentives.

The stock options will vest over four years, with 25% vesting on the first anniversary and the remaining vesting monthly at 1/48th of the total shares, contingent on continued employment. The grants were made under NYSE's Listed Company Manual Rule 303A.08's employment inducement exemption.

ADC Therapeutics (NYSE: ADCT) ha concesso opzioni su azioni a due nuovi dipendenti per acquistare un totale di 128.600 azioni ordinarie, a partire dal 1 aprile 2025. Le concessioni, approvate dal Comitato per la Compensazione della Società nell'ambito del Piano di Induzione, fungono da incentivi materiali all'occupazione.

Le opzioni su azioni matureranno in quattro anni, con il 25% che matura al primo anniversario e il restante che matura mensilmente a 1/48 del totale delle azioni, subordinato al mantenimento dell'impiego. Le concessioni sono state effettuate ai sensi dell'esenzione per induzione all'occupazione prevista dalla Regola 303A.08 del Manuale delle Aziende Quotati della NYSE.

ADC Therapeutics (NYSE: ADCT) ha otorgado opciones sobre acciones a dos nuevos empleados para comprar un total de 128,600 acciones ordinarias, con efecto a partir del 1 de abril de 2025. Las concesiones, aprobadas por el Comité de Compensación de la Compañía bajo el Plan de Inducción, sirven como incentivos materiales para el empleo.

Las opciones sobre acciones se consolidarán en cuatro años, con el 25% consolidándose en el primer aniversario y el resto consolidándose mensualmente a 1/48 del total de acciones, condicionado a la continuidad del empleo. Las concesiones se realizaron bajo la exención de inducción al empleo de la Regla 303A.08 del Manual de Empresas Cotizadas de la NYSE.

ADC Therapeutics (NYSE: ADCT)는 두 명의 신입 직원에게 총 128,600주를 구매할 수 있는 주식 옵션을 부여했습니다. 이 옵션은 2025년 4월 1일부터 유효합니다. 이 부여는 회사의 보상 위원회에 의해 유도 계획에 따라 승인된 것으로, 실질적인 고용 인센티브 역할을 합니다.

주식 옵션은 4년에 걸쳐 발생합니다, 첫 번째 기념일에 25%가 발생하고 나머지는 총 주식의 1/48씩 매월 발생하며, 지속적인 고용에 따라 달라집니다. 이 부여는 NYSE의 상장 기업 매뉴얼 규칙 303A.08의 고용 유도 면제에 따라 이루어졌습니다.

ADC Therapeutics (NYSE: ADCT) a accordé des options d'achat d'actions à deux nouveaux employés pour acquérir un total de 128 600 actions ordinaires, à compter du 1er avril 2025. Les attributions, approuvées par le Comité de Rémunération de la Société dans le cadre du Plan d'Incitation, servent d'incitations matérielles à l'emploi.

Les options d'achat d'actions s'acquitteront sur quatre ans, avec 25 % s'acquittant au premier anniversaire et le reste s'acquittant mensuellement à 1/48 du total des actions, sous réserve de la poursuite de l'emploi. Les attributions ont été effectuées dans le cadre de l'exemption d'incitation à l'emploi de la règle 303A.08 du Manuel des Sociétés Cotées de la NYSE.

ADC Therapeutics (NYSE: ADCT) hat zwei neuen Mitarbeitern Aktienoptionen gewährt, um insgesamt 128.600 Stammaktien zu erwerben, die ab dem 1. April 2025 wirksam sind. Die Zuteilungen, die vom Vergütungsausschuss des Unternehmens im Rahmen des Induktionsplans genehmigt wurden, dienen als materielle Anreize für die Beschäftigung.

Die Aktienoptionen werden über vier Jahre fällig, wobei 25% am ersten Jahrestag fällig werden und der Rest monatlich zu 1/48 der Gesamtaktien fällig wird, abhängig von der fortgesetzten Beschäftigung. Die Zuteilungen wurden gemäß der Ausnahmeregelung für Beschäftigungsanreize gemäß Regel 303A.08 des Leitfadens für börsennotierte Unternehmen der NYSE vorgenommen.

Positive
  • Employee retention strategy implemented through stock-based compensation
  • Alignment of new employee interests with shareholder value
Negative
  • Potential shareholder dilution from 128,600 new stock options

LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 128,600 of the Company's common shares to two new employees on April 1, 2025 (each, a "Grant").

The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:

Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450

Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302414722.html

SOURCE ADC Therapeutics SA

FAQ

How many stock options did ADC Therapeutics grant to new employees in April 2025?

ADC Therapeutics granted options to purchase 128,600 common shares to two new employees on April 1, 2025.

What is the vesting schedule for ADCT's April 2025 employee stock options?

The options vest 25% after one year, followed by 1/48th monthly over the next three years, fully vesting after four years.

Under which rule were ADCT's employee stock options granted in April 2025?

The grants were made under NYSE's Listed Company Manual Rule 303A.08's employment inducement exemption.

Who approved the ADCT stock option grants issued in April 2025?

The grants were approved by the Compensation Committee of ADC Therapeutics' Board of Directors.
Adc Therapeutics Sa

NYSE:ADCT

ADCT Rankings

ADCT Latest News

ADCT Stock Data

120.88M
71.77M
20.64%
63.17%
5.48%
Biotechnology
Pharmaceutical Preparations
Link
Switzerland
EPALINGES